Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

XRTX

XORTX Therapeutics Inc

Apr 18 • 04:00PM ET

3.05

Dollar change -0.12
Percentage change -3.78	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	10.30%	Shs Outstand	2.00M	Perf Week	-14.20%
Market Cap	6.10M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	0.00%	Shs Float	1.79M	Perf Month	-38.38%
Income	-2.16M	PEG	-	EPS next Q	-0.45	Inst Own	23.95%	Short Float	1.18%	Perf Quarter	35.56%
Sales	0.00M	P/S	-	EPS this Y	-63.97%	Inst Trans	-	Short Ratio	0.43	Perf Half Y	12.59%
Book/sh	2.32	P/B	1.31	EPS next Y	46.29%	ROA	-24.20%	Short Interest	0.02M	Perf Year	-51.86%
Cash/sh	1.73	P/C	1.77	EPS next 5Y	-	ROE	-37.12%	52W Range	1.98 - 8.01	Perf YTD	32.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.21%	ROI	-46.49%	52W High	-61.92%	Beta	-
Dividend TTM	-	Quick Ratio	12.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	54.05%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	12.70	EPS Y/Y TTM	77.23%	Oper. Margin	0.00%	RSI (14)	40.20	Volatility	8.67% 11.15%
Employees	17	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.15
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	201.85%	Payout	-	Rel Volume	0.62	Prev Close	3.17
Sales Surprise	-	EPS Surprise	304.14%	Sales Q/Q	-	Earnings	Apr 02 BMO	Avg Volume	49.07K	Price	3.05
SMA20	-17.26%	SMA50	-14.30%	SMA200	-22.36%	Trades		Volume	30,656	Change	-3.78%

Apr-08-24 07:30AM	XORTX Welcomes New Member to the Board of Directors (GlobeNewswire) +5.53%
07:00AM	XORTX Announces Participation in Spring 2024 Investor Conferences (GlobeNewswire)
Mar-27-24 05:00AM	XORTX Announces New Clinical Advisory Board Member (GlobeNewswire) -5.26%
Mar-19-24 09:30AM	XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial (News Direct)
05:00AM	XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial (GlobeNewswire)
07:00AM	Loading…
Mar-11-24 07:00AM	XORTX Reprices Warrants Issued in Connection with Previous Private Placements (GlobeNewswire) -6.71%
Mar-04-24 07:00AM	XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units (GlobeNewswire) +5.06%
Feb-15-24 07:00AM	XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units (GlobeNewswire)
Feb-01-24 08:46PM	XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units (GlobeNewswire)
Jan-15-24 07:00AM	XORTX Announces $2 Million Public Offering (GlobeNewswire)
Jan-03-24 07:00AM	XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease (GlobeNewswire) +13.18%
Jan-02-24 07:00AM	XORTX Welcomes New Member to the Board of Directors (GlobeNewswire)
Nov-30-23 07:30AM	XORTX Announces US ATM Offering (GlobeNewswire) -19.74%
Nov-29-23 07:00AM	XORTX Meets Nasdaq Continued Listing Requirements (GlobeNewswire)
Nov-10-23 07:00AM	XORTX Clarifies Timing for Share Consolidation (GlobeNewswire)
05:00PM	Loading…
Nov-08-23 05:00PM	XORTX Announces Share Consolidation (GlobeNewswire) -6.20%
Nov-02-23 07:00AM	XORTX Sponsored Study Presented at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-27-23 05:30PM	XORTX Announces Results of Special Meeting of Shareholders (GlobeNewswire) -14.34%
Oct-25-23 05:00PM	XORTX Announces Date for Rescheduled Special Meeting of Shareholders (GlobeNewswire) -14.56%
07:00AM	XORTX Announces Rescheduling of Special Meeting of Shareholders (GlobeNewswire)
Oct-23-23 09:10AM	Why Is Xortx Therapeutics (XRTX) Stock Down 27% Today? (InvestorPlace) -34.18%
Oct-20-23 08:42AM	Why Is Xortx Therapeutics (XRTX) Stock Up 110% Today? (InvestorPlace) +83.09%
Oct-12-23 07:00AM	XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution (GlobeNewswire) -10.26%
Oct-04-23 07:00AM	XORTX Calls Special Meeting of Shareholders (GlobeNewswire) -23.41%
Sep-28-23 07:00AM	XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Sep-11-23 07:00AM	XORTX Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-07-23 07:00AM	XORTX Joins the Kidney Foundation and Kidney March (GlobeNewswire) -5.22%
Aug-29-23 07:00AM	XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease (GlobeNewswire)
Aug-04-23 05:00PM	XORTX Appoints Chief Financial Officer (GlobeNewswire)
Jun-29-23 08:00AM	XORTX Announces Results of Annual and Special Meeting of Shareholders (GlobeNewswire) -7.72%
08:51PM	Loading…
Jun-23-23 08:51PM	XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Companys Upcoming Annual and Special Meeting of Shareholders (GlobeNewswire)
Jun-06-23 07:00AM	XORTX Announces PKD Presentation (GlobeNewswire)
May-24-23 07:00AM	XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) +8.11%
May-04-23 07:00AM	FDA Confirms Eligibility of XORLO for Accelerated Approval (GlobeNewswire)
Apr-21-23 07:00AM	XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease (GlobeNewswire)
Mar-14-23 07:00AM	XORTX Announces Type D Meeting with FDA to be held May 1, 2023 (GlobeNewswire)
Feb-07-23 07:00AM	XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones (GlobeNewswire)
Feb-01-23 07:00AM	XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease (GlobeNewswire) +8.47%
Jan-19-23 07:00AM	XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial (GlobeNewswire) +11.14%
Jan-03-23 07:00AM	XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression (GlobeNewswire)
Dec-19-22 07:00AM	XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study (GlobeNewswire) -6.68%
Dec-08-22 07:00AM	XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire)
Nov-28-22 07:00AM	XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study (GlobeNewswire)
Nov-25-22 05:45PM	XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +14.62%
Nov-16-22 07:00AM	XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer (GlobeNewswire) -8.96%
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
Nov-03-22 05:00PM	XORTX Presents New Proof of Concept Data at American Society of Nephrology (GlobeNewswire)
10:15AM	XORTX Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-26-22 07:00AM	XORTX Receives Further No Objection Letter from Health Canada (GlobeNewswire)
Oct-25-22 07:00AM	XORTX Sponsored American Society of Nephrology Study Abstract Available Online (GlobeNewswire)
Oct-07-22 06:02PM	XORTX Announces Closing of US$5 Million Public Offering (GlobeNewswire)
Oct-04-22 08:30AM	XORTX Announces US$5 Million Public Offering (GlobeNewswire) -14.28%
Sep-19-22 07:00AM	XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration (GlobeNewswire) -7.03%
Sep-01-22 07:00AM	XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology Kidney Week 2022 (GlobeNewswire)
Aug-22-22 07:00AM	XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study (GlobeNewswire) +9.27%
Aug-04-22 07:00AM	XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration (GlobeNewswire) +5.58%
Jul-22-22 08:00AM	XORTX Reports Annual & Special Meeting Results (GlobeNewswire)
Jul-19-22 07:00AM	XORTX Announces Submission to European Medicines Agency (GlobeNewswire) -8.70%
Jul-13-22 07:00AM	XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial (GlobeNewswire) +48.36%
Jul-07-22 07:00AM	XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA) (GlobeNewswire) +7.82%
Jun-21-22 07:00AM	XORTX Announces Fireside Chat with XORTX CEO (GlobeNewswire)
Jun-13-22 08:55AM	XORTX to Present at BIO International Convention 2022 (GlobeNewswire) -12.34%
Jun-08-22 07:00AM	XORTX to Present at LD Micro Invitational 2022 (GlobeNewswire)
Jun-06-22 07:00AM	XORTX Welcomes New Member to the Board of Directors and Appoints Chair (GlobeNewswire) +11.72%
May-25-22 08:00AM	XORTX to Present at H. C. Wainwright Global Investment Conference 2022 (GlobeNewswire) -7.06%
May-05-22 07:00AM	XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire) +8.75%
May-03-22 07:00AM	XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial (GlobeNewswire) +57.76%
Apr-20-22 07:00AM	XORTX Receives Small and Medium Enterprise Status for the European Union (GlobeNewswire)
Apr-12-22 07:00AM	XORTX Receives No Objection Letter from Health Canada (GlobeNewswire)
Apr-07-22 07:00AM	XORTX Announces Grant of US Patent (GlobeNewswire)
Mar-31-22 07:00AM	XORTX Files IND with US FDA (GlobeNewswire)
Mar-23-22 07:00AM	XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection (GlobeNewswire) +43.80%
Mar-14-22 07:00AM	XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study (GlobeNewswire)
Jan-31-22 07:00AM	XORTX Provides Corporate Update (GlobeNewswire)
Jan-20-22 07:00AM	XORTX Announces Appointment of Chief Technology Officer (GlobeNewswire)
Jan-12-22 08:30AM	Nanalysis Announces the Closing of Acquisition of K'(Prime) Technologies Inc. (PR Newswire) -7.80%
Jan-10-22 07:00AM	XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-22-21 08:30AM	Nanalysis Establishes Scientific Advisory Board with Four World Renowned Scientists (PR Newswire)
Dec-21-21 06:00PM	XORTX Reports Annual & Special Meeting Results (GlobeNewswire)
07:00AM	XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease (GlobeNewswire)
Dec-10-21 07:01AM	XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients (GlobeNewswire) -6.38%
Dec-09-21 11:53AM	Companies Like XORTX Therapeutics (CVE:XRTX) Can Afford To Invest In Growth (Simply Wall St.)
09:30AM	TMX Group Equity Financing Statistics - November 2021 (PR Newswire)
08:04AM	XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners (GlobeNewswire)
Dec-02-21 07:00AM	XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study (GlobeNewswire) -6.31%
Nov-23-21 07:00AM	XORTX Therapeutics Announces Annual and Special Meeting of Shareholders (GlobeNewswire) -8.33%
Nov-15-21 08:00AM	Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX) (PR Newswire) +9.09%
Nov-09-21 07:00AM	XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering (GlobeNewswire) -13.71%
Nov-05-21 08:11AM	IIROC Trading Resumption - XRTX (PR Newswire)
Nov-04-21 02:49PM	XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange (GlobeNewswire)
08:21AM	IIROC Trading Halt - XRX (PR Newswire)
Nov-02-21 06:13PM	XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange (GlobeNewswire)
Oct-15-21 05:38PM	XORTX Therapeutics Announces Closing of US$12 Million Public Offering (GlobeNewswire) -6.21%
Oct-14-21 05:30PM	XORTX Announces Results from Mount Sinais COVID-19 Clinical Study (GlobeNewswire)
07:00AM	XORTX to Present at the LD Micro Main Event (GlobeNewswire)

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XRTX

XORTX Therapeutics Inc

Upgrade your FINVIZ experience